Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 2/20 | 0.38 |
| ▸ | AKT1 | P31749 | 2/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | AKT2 | P31751 | 1/20 | 0.38 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
| ▸ | GPR6 | P46095 | 1/20 | 0.35 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.35 |
| ▸ | SMO | Q99835 | 1/20 | 0.35 |
| ▸ | DCAF15 | Q66K64 | 1/20 | 0.35 |
| ▸ | GPR174 | Q9BXC1 | 1/20 | 0.35 |
| ▸ | GBA1 | P04062 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2113480 | 1.00 | NCF1 (0.38) | NCF1AKT1ACHEBACE1AKT2 | |
| SCHEMBL2115753 | 0.83 | AKT1 (0.41) | NCF1AKT1PIK3CDGPR6 | |
| SCHEMBL2115704 | 0.77 | NCF1 (0.49) | NCF1PIK3CDSMOGBA1 | |
| SCHEMBL2115701 | 0.77 | NCF1 (0.49) | NCF1PIK3CDSMOGBA1 | |
| SCHEMBL2115290 | 0.76 | PRKCH (0.37) | GRIA1 | |
| SCHEMBL2115287 | 0.76 | PRKCH (0.37) | GRIA1 | |
| SCHEMBL2117481 | 0.76 | KRAS (0.40) | GPR6GRIA1 | |
| SCHEMBL2117482 | 0.76 | KRAS (0.40) | GPR6GRIA1 | |
| SCHEMBL2114935 | 0.75 | SOS1 (0.38) | AKT1ACHEBACE1AKT2AKT3 | |
| SCHEMBL2114937 | 0.75 | SOS1 (0.38) | AKT1ACHEBACE1AKT2AKT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120095005-A1 | Fused Bicyclic Pyrazole Derivatives As Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095005-A1 | Fused Bicyclic Pyrazole Derivatives As Kinase Inhibitors | PI4KA, PDPK1, PIK3CA | NCF1 2116/4885AKT1 290/4885ACHE 625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.